tetano
Editor, Senior Moderator
J Allergy Clin Immunol. 2019 Jan 14. pii: S0091-6749(19)30020-X. doi: 10.1016/j.jaci.2018.12.1003. [Epub ahead of print]
[h=1]Anaphylaxis After Vaccination Reported To The Vaccine Adverse Event Reporting System, 1990-2016.[/h] Su JR[SUP]1[/SUP], Moro PL[SUP]2[/SUP], Ng C[SUP]2[/SUP], Lewis PW[SUP]2[/SUP], Said MA[SUP]3[/SUP], Cano MV[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Anaphylaxis, a rare, potentially life-threatening hypersensitivity reaction, can occur after vaccination.
[h=4]OBJECTIVE:[/h] Describe reports of anaphylaxis after vaccination to the Vaccine Adverse Event Reporting System (VAERS) during 1990-2016.
[h=4]METHODS:[/h] We identified domestic reports of anaphylaxis within VAERS using a combination of Medical Dictionary for Regulatory Activity queries and Preferred Terms. We performed descriptive analysis, including history of hypersensitivity (e.g., anaphylaxis, respiratory allergies, drug allergies), and vaccines given. We reviewed all serious reports, and all non-serious reports with available medical records, to determine if they met the Brighton Collaboration case definition (BCCD) for anaphylaxis or were diagnosed by a physician.
[h=4]RESULTS:[/h] During the analytic period, VAERS received 467,960 total reports; 828 met BCCD for or were physician-diagnosed as anaphylaxis: 654 (79%) were classified as serious, and 669 (81%) had medical records available. Of 478 reports in children aged <19 years, 65% were male; childhood vaccines were most commonly reported. Of 350 reports in persons aged ≥19 years, 80% were female, and influenza vaccines were most frequently reported. Overall, 41% of reports described persons with no history of hypersensitivity. We identified 8 deaths, 4 among persons with no history of hypersensitivity.
[h=4]CONCLUSION:[/h] Anaphylaxis after vaccination is rare in the United States, and can occur among persons with no history of hypersensitivity. Most persons recover fully with treatment, but serious complications, including death, can occur.
Copyright ? 2019. Published by Elsevier Inc.
[h=4]KEYWORDS:[/h] Brighton; VAERS; adverse event; anaphylaxis; epidemiology; hypersensitivity; vaccine
PMID: 30654049 DOI: 10.1016/j.jaci.2018.12.1003
[h=1]Anaphylaxis After Vaccination Reported To The Vaccine Adverse Event Reporting System, 1990-2016.[/h] Su JR[SUP]1[/SUP], Moro PL[SUP]2[/SUP], Ng C[SUP]2[/SUP], Lewis PW[SUP]2[/SUP], Said MA[SUP]3[/SUP], Cano MV[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Anaphylaxis, a rare, potentially life-threatening hypersensitivity reaction, can occur after vaccination.
[h=4]OBJECTIVE:[/h] Describe reports of anaphylaxis after vaccination to the Vaccine Adverse Event Reporting System (VAERS) during 1990-2016.
[h=4]METHODS:[/h] We identified domestic reports of anaphylaxis within VAERS using a combination of Medical Dictionary for Regulatory Activity queries and Preferred Terms. We performed descriptive analysis, including history of hypersensitivity (e.g., anaphylaxis, respiratory allergies, drug allergies), and vaccines given. We reviewed all serious reports, and all non-serious reports with available medical records, to determine if they met the Brighton Collaboration case definition (BCCD) for anaphylaxis or were diagnosed by a physician.
[h=4]RESULTS:[/h] During the analytic period, VAERS received 467,960 total reports; 828 met BCCD for or were physician-diagnosed as anaphylaxis: 654 (79%) were classified as serious, and 669 (81%) had medical records available. Of 478 reports in children aged <19 years, 65% were male; childhood vaccines were most commonly reported. Of 350 reports in persons aged ≥19 years, 80% were female, and influenza vaccines were most frequently reported. Overall, 41% of reports described persons with no history of hypersensitivity. We identified 8 deaths, 4 among persons with no history of hypersensitivity.
[h=4]CONCLUSION:[/h] Anaphylaxis after vaccination is rare in the United States, and can occur among persons with no history of hypersensitivity. Most persons recover fully with treatment, but serious complications, including death, can occur.
Copyright ? 2019. Published by Elsevier Inc.
[h=4]KEYWORDS:[/h] Brighton; VAERS; adverse event; anaphylaxis; epidemiology; hypersensitivity; vaccine
PMID: 30654049 DOI: 10.1016/j.jaci.2018.12.1003